We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Resverlogix Presents Important New Data at the ASN Kidney Week Conference

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Resverlogix Presents Important New Data at the ASN Kidney Week Conference"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Resverlogix Corp. has announced the presentation of important new data detailing the actions of apabetalone (RVX-208) in cardiovascular disease (CVD) and chronic kidney disease (CKD) patients at the American Society of Nephrology (ASN) Kidney Week conference in San Diego, CA, USA. The data was summarized in two poster presentations.

The first was entitled 'Apabetalone, a First-in-Class Epigenetic BET-Inhibitor, has Effects on Alkaline Phosphatase (ALP) and Estimated Glomerular Filtration Rate (eGFR) in Subjects with CVD and CKD; a Post-hoc Analysis of the ASSERT, SUSTAIN and ASSURE Clinical Trials'.

The data contained in this presentation showed that in patients with a baseline eGFR<60 mL/min/1.73 m2, treatment with RVX-208 for 12-26 weeks lead to an improvement in eGFR and a significant reduction in ALP (p<0.01).

In the second presentation entitled 'Alkaline Phosphatase Lowering by Selective BET inhibition, a Novel Mechanism for Major Adverse Cardiac Events (MACE) Reduction in High Risk CVD, Diabetes and CKD Patients, a Post-hoc Analysis of Phase 2b Studies with Apabetalone'.

This presentation contained data gathered in the SUSTAIN and ASSURE trials showing that baseline ALP levels were significantly higher in all patients who suffered from MACE versus those who were free from MACE. One of the most significant findings was in apabetalone treated patients (n=331).

In this treated population, patients who suffered from MACE had an increase of ALP by 3 IU/L vs. baseline, while in the event free patients (n=313) ALP decreased by 8 IU/L. This absolute difference of 11 IU/L between these two groups was significant (p=0.02).

In addition to the Company's presentations listed above, Dr. Kam Kalantar-Zadeh, Professor and Chief, Division of Nephrology and Hypertension at University of California Irvine, highlighted some of the above findings during an oral presentation titled, "Clinical Practice Session: Hot Topics in CKD–MBD: Where Do We Stand in 2015 in Management of Bones and Minerals."

Dr. Kalantar-Zadeh's presentation focused on the importance of ALP as a prognostic biomarker in CVD and CKD patients. The Company continues to review these and additional findings for potential peer reviewed journal publications.